# Nal-iri/lv5-fu Versus Paclitaxel as Second Line Therapy in Patients With Metastatic Oesophageal Squamous Cell Carcinoma

> **NCT03719924** · PHASE2 · COMPLETED · sponsor: **Federation Francophone de Cancerologie Digestive** · enrollment: 106 (actual)

## Conditions studied

- Squamous Cell Carcinoma

## Interventions

- **DRUG:** Onivyde
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT03719924
- **Lead sponsor:** Federation Francophone de Cancerologie Digestive
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-07
- **Primary completion:** 2024-04-15
- **Final completion:** 2024-09-29
- **Target enrollment:** 106 (ACTUAL)
- **Last updated:** 2025-01-08

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03719924

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03719924, "Nal-iri/lv5-fu Versus Paclitaxel as Second Line Therapy in Patients With Metastatic Oesophageal Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03719924. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*